# Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension

> **NCT00454207** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 44 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** sildenafil citrate (UK-92,480)

## Key facts

- **NCT ID:** NCT00454207
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454207, "Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00454207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*